Brokerages expect Context Therapeutics Inc. (NASDAQ:CNTX – Get Rating) to report ($0.24) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Context Therapeutics’ earnings. The firm is scheduled to report its next earnings report on Monday, January 1st.
On average, analysts expect that Context Therapeutics will report full-year earnings of ($1.16) per share for the current fiscal year, with EPS estimates ranging from ($1.30) to ($1.01). For the next year, analysts anticipate that the company will report earnings of ($1.68) per share, with EPS estimates ranging from ($1.95) to ($1.40). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Context Therapeutics.
Several brokerages have weighed in on CNTX. Zacks Investment Research upgraded Context Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. HC Wainwright began coverage on Context Therapeutics in a report on Wednesday, February 2nd. They set a “buy” rating and a $6.00 price objective for the company. Finally, ThinkEquity began coverage on Context Therapeutics in a report on Monday, January 24th. They set a “buy” rating and a $10.00 price objective for the company.
NASDAQ:CNTX traded up $0.01 during midday trading on Monday, reaching $1.45. The company had a trading volume of 37,356 shares, compared to its average volume of 420,811. The business’s fifty day simple moving average is $1.96. Context Therapeutics has a 12-month low of $1.30 and a 12-month high of $10.87.
Context Therapeutics Company Profile (Get Rating)
Context Therapeutics Inc, a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as ovarian, uterine (endometrial), and breast cancers.
- Get a free copy of the StockNews.com research report on Context Therapeutics (CNTX)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.